Zenosense, Inc. engages in developing medical devices for the diagnosis of heart attack and cardiac-related illnesses. It includes the detection of the Methicillin-resistant Staphylococcus aureus. The firm uses Acute Myocardial Infarction, and MIDS Cardiac technologies. The company was founded on August 11, 2008 and is headquartered in New Haven, CT.